Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Can Passkey Therapeutics turn drug combinations into a faster clinical strategy?

AI drug platforms need clinical proof. Passkey’s new CMO must show whether Locksmith-picked combinations can move faster into patients.

Read More
Pharma & Biotech

How Eli Lilly and Company is positioning VERVE-102 at the center of cardiovascular gene editing

Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.

Read More
Representative image of Alzheimer’s disease treatment and market analysis, highlighting how Eisai’s Leqembi sales simulation could shape BioArctic’s royalty outlook, investor sentiment and the commercial future of anti-amyloid therapies.
Pharma & Biotech

Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it

Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.

Read More
Representative image: A sterile pharmaceutical manufacturing suite with isolator-based closed processing equipment, illustrating how Curia’s Valladolid aseptic API upgrade could strengthen contamination control, Annex 1 readiness and CDMO sterile manufacturing capacity.
Pharma & Biotech

Can Curia’s Valladolid upgrade raise the bar for sterile API manufacturing?

Find out how Curia’s $4m Valladolid aseptic suite upgrade could strengthen sterile API manufacturing and Annex 1 readiness.

Read More
Representative image: A scientist reviews sequencing-style quality control data in a modern biopharma lab, illustrating how Oxford Nanopore Technologies and Lonza aim to improve GMP mRNA testing, release workflows and advanced therapy manufacturing.
Pharma & Biotech

Can Oxford Nanopore and Lonza fix the mRNA quality control bottleneck?

Find out how Oxford Nanopore and Lonza’s GMP mRNA QC solution could simplify release testing for next-generation RNA medicines.

Read More
Pharma & Biotech

Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment

Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.

Read More
Pharma & Biotech

Can United Immunity revive macrophage cell therapy after Carisma’s reset?

Macrophage cell therapy has promise but painful execution risk. United Immunity’s Carisma deal tests whether in vivo CAR-M can scale.

Read More
Pharma & Biotech

Lupin just cracked China with a flu drug. Why investors may want to look closer

Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.

Read More
Representative image: A sterile radiopharmaceutical manufacturing cleanroom with shielded processing equipment and sealed vials, illustrating how Niowave’s Michigan Actinium-225 facility could support the next phase of targeted cancer therapy supply.
Pharma & Biotech

Can Niowave’s Michigan facility ease the Actinium-225 bottleneck in cancer therapy?

Find out how Niowave’s $75m Michigan facility could reshape Actinium-225 supply for targeted cancer therapies.

Read More
Pharma & Biotech

Coya Therapeutics advances COYA 302 as FDA fast track status raises clinical expectations

Coya Therapeutics’ COYA 302 fast track status raises the stakes for Treg-based ALS therapy. Find out what comes next.

Read More